Abstract

The contact system includes factor XII (FXII), FXI, prekallikrein (PK), and high-molecular-weight kininogen (HK), and has received increased interest as a potential target in immunothrombotic and inflammatory diseases. This system activates 2 distinct pathways, the intrinsic pathway of coagulation via cleavage of FIX, and inflammation via HK cleavage resulting in bradykinin (BK) generation. HK is central to the function of both arms of the system as a substrate for plasma kallikrein and critical cofactor, which forms interactions with cell receptors and activators. Both FXI and PK circulate in complex with HK and both can be cleaved by activated FXII. Reciprocal activation and continuous consumption of PK and FXII is a feature of the contact system. On endothelial cells, PK and FXII become activated but only in the presence of secreted receptor for the globular domain of C1q and Zn2+ ions. A second mechanism exists on endothelial cells whereby prolylcarboxypeptidase activates the PK-HK complex to generate BK in an FXII-independent manner. On platelets, FXI can be cleaved by thrombin, but only in the presence of secreted polyphosphate. This review explores the 3-dimensional structure of the contact factors and examines the molecular mechanisms underlying contact activation. We focus on conformational changes that expose cleavage sites and exosites in FXII, PK, and FXI. We also discuss contact factor protein-protein interactions, recognition of polyanions, and the role of HK and Zn2+ in contact system assembly.

1.
Pathak
M
,
Kaira
BG
,
Slater
A
,
Emsley
J
.
Cell receptor and cofactor interactions of the contact activation system and factor XI
.
Front Med (Lausanne)
.
2018
;
5
:
66
.
2.
Rangaswamy
C
,
Englert
H
,
Deppermann
C
,
Renné
T
.
Polyanions in coagulation and thrombosis: focus on polyphosphate and neutrophils extracellular traps
.
Thromb Haemost
.
2021
;
121
(
8
):
1021
-
1030
.
3.
Mahdi
F
,
Madar
ZS
,
Figueroa
CD
,
Schmaier
AH
.
Factor XII interacts with the multiprotein assembly of urokinase plasminogen activator receptor, gC1qR, and cytokeratin 1 on endothelial cell membranes
.
Blood
.
2002
;
99
(
10
):
3585
-
3596
.
4.
Pixley
RA
,
Espinola
RG
,
Ghebrehiwet
B
, et al
.
Interaction of high-molecular-weight kininogen with endothelial cell binding proteins suPAR, gC1qR and cytokeratin 1 determined by surface plasmon resonance (BiaCore)
.
Thromb Haemost
.
2011
;
105
(
6
):
1053
-
1059
.
5.
Fandaros
M
,
Joseph
K
,
Kaplan
AP
,
Rubenstein
DA
,
Ghebrehiwet
B
,
Yin
W
.
gC1qR antibody can modulate endothelial cell permeability in angioedema
.
Inflammation
.
2022
;
45
(
1
):
116
-
128
.
6.
Merkulova
AA
,
Abdalian
S
,
Silbak
S
,
Pinheiro
A
,
Schmaier
AH
.
C1 inhibitor and prolylcarboxypeptidase modulate prekallikrein activation on endothelial cells
.
J Allergy Clin Immunol
.
2023
;
152
(
4
):
961
-
971.e7
.
7.
Shamanaev
A
,
Ivanov
I
,
Sun
MF
, et al
.
Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains
.
Blood Adv
.
2022
;
6
(
10
):
3142
-
3154
.
8.
Mandle
RJ
,
Colman
RW
,
Kaplan
AP
.
Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma
.
Proc Natl Acad Sci U S A
.
1976
;
73
(
11
):
4179
-
4183
.
9.
Meier
HL
,
Pierce
JV
,
Colman
RW
,
Kaplan
AP
.
Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein
.
J Clin Invest
.
1977
;
60
(
1
):
18
-
31
.
10.
White-Adams
TC
,
Berny
MA
,
Tucker
EI
, et al
.
Identification of coagulation factor XI as a ligand for platelet apolipoprotein E receptor 2 (ApoER2)
.
Arterioscler Thromb Vasc Biol
.
2009
;
29
(
10
):
1602
-
1607
.
11.
Mohammed
BM
,
Matafonov
A
,
Ivanov
I
, et al
.
An update on factor XI structure and function
.
Thromb Res
.
2018
;
161
:
94
-
105
.
12.
Chan
NC
,
Weitz
JI
.
New therapeutic targets for the prevention and treatment of venous thromboembolism with a focus on factor XI inhibitors
.
Arterioscler Thromb Vasc Biol
.
2023
;
43
(
10
):
1755
-
1763
.
13.
Gailani
D
,
Gruber
A
.
Targeting factor XI and factor XIa to prevent thrombosis
.
Blood
.
2024
;
143
(
15
):
1465
-
1475
.
14.
Petersen
RS
,
Fijen
LM
,
Levi
M
,
Cohn
DM
.
Hereditary angioedema: the clinical picture of excessive contact activation
.
Semin Thromb Hemost
.
2024
;
50
(
7
):
978
-
988
.
15.
Wisniewski
P
,
Gangnus
T
,
Burckhardt
BB
.
Recent advances in the discovery and development of drugs targeting the kallikrein-kinin system
.
J Transl Med
.
2024
;
22
(
1
):
388
.
16.
Sundler Björkman
L
,
Pirouzifard
M
,
Grover
SP
, et al
.
Increased risk of venous thromboembolism in young and middle-aged individuals with hereditary angioedema: a family study
.
Blood
.
2024
;
144
(
4
):
435
-
444
.
17.
Hofman
ZLM
,
Clark
CC
,
Sanrattana
W
, et al
.
A mutation in the kringle domain of human factor XII that causes autoinflammation, disturbs zymogen quiescence, and accelerates activation
.
J Biol Chem
.
2020
;
295
(
2
):
363
-
374
.
18.
Cichon
S
,
Martin
L
,
Hennies
HC
, et al
.
Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III
.
Am J Hum Genet
.
2006
;
79
(
6
):
1098
-
1104
.
19.
Dewald
G
,
Bork
K
.
Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor
.
Biochem Biophys Res Commun
.
2006
;
343
(
4
):
1286
-
1289
.
20.
Prieto
A
,
Tornero
P
,
Rubio
M
,
Fernández-Cruz
E
,
Rodriguez-Sainz
C
.
Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III
.
Allergy
.
2009
;
64
(
2
):
284
-
286
.
21.
Clark
CC
,
Hofman
ZLM
,
Sanrattana
W
,
den Braven
L
,
de Maat
S
,
Maas
C
.
The fibronectin type II domain of factor XII ensures zymogen quiescence
.
Thromb Haemost
.
2020
;
120
(
3
):
400
-
411
.
22.
Zhang
H
,
Löwenberg
EC
,
Crosby
JR
, et al
.
Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
.
Blood
.
2010
;
116
(
22
):
4684
-
4692
.
23.
Yau
JW
,
Liao
P
,
Fredenburgh
JC
, et al
.
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
.
Blood
.
2014
;
123
(
13
):
2102
-
2107
.
24.
Clermont
AC
,
Murugesan
N
,
Edwards
HJ
, et al
.
Oral FXIIa inhibitor KV998086 suppresses FXIIa and single chain FXII mediated kallikrein kinin system activation
.
Front Pharmacol
.
2023
;
14
:
1287487
.
25.
Xu
P
,
Zhang
Y
,
Guo
J
, et al
.
A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation
.
Nat Commun
.
2024
;
15
(
1
):
7898
.
26.
Philippou
H
,
Stavrou
EX
.
Next generation anticoagulants: a spotlight on the potential role of activated factors XII and XI
.
Expert Rev Hematol
.
2023
;
16
(
10
):
711
-
714
.
27.
Cool
DE
,
Edgell
CJ
,
Louie
GV
,
Zoller
MJ
,
Brayer
GD
,
MacGillivray
RT
.
Characterization of human blood coagulation factor XII cDNA. Prediction of the primary structure of factor XII and the tertiary structure of beta-factor XIIa
.
J Biol Chem
.
1985
;
260
(
25
):
13666
-
13676
.
28.
Heestermans
M
,
Naudin
C
,
Mailer
RK
, et al
.
Identification of the factor XII contact activation site enables sensitive coagulation diagnostics
.
Nat Commun
.
2021
;
12
(
1
):
5596
.
29.
Maas
C
,
Govers-Riemslag
JW
,
Bouma
B
, et al
.
Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation
.
J Clin Invest
.
2008
;
118
(
9
):
3208
-
3218
.
30.
Kaira
BG
,
Slater
A
,
McCrae
KR
, et al
.
Factor XII and kininogen asymmetric assembly with gC1qR/C1QBP/P32 is governed by allostery
.
Blood
.
2020
;
136
(
14
):
1685
-
1697
.
31.
Stavrou
EX
,
Fang
C
,
Bane
KL
, et al
.
Factor XII and uPAR upregulate neutrophil functions to influence wound healing
.
J Clin Invest
.
2018
;
128
(
3
):
944
-
959
.
32.
Pathak
M
,
Wilmann
P
,
Awford
J
, et al
.
Coagulation factor XII protease domain crystal structure
.
J Thromb Haemost
.
2015
;
13
(
4
):
580
-
591
.
33.
Dementiev
A
,
Silva
A
,
Yee
C
, et al
.
Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors
.
Blood Adv
.
2018
;
2
(
5
):
549
-
558
.
34.
Drulyte
I
,
Ghai
R
,
Ow
SY
, et al
.
Structural basis for the inhibition of βFXIIa by garadacimab
.
Structure
.
2024
;
32
(
10
):
1705
-
1710.e3
.
35.
Beringer
DX
,
Kroon-Batenburg
LM
.
The structure of the FnI-EGF-like tandem domain of coagulation factor XII solved using SIRAS
.
Acta Crystallogr Sect F Struct Biol Cryst Commun
.
2013
;
69
(
pt 2
):
94
-
102
.
36.
Frunt
R
,
El Otmani
H
,
Gibril Kaira
B
,
de Maat
S
,
Maas
C
.
Factor XII explored with alphafold - opportunities for selective drug development
.
Thromb Haemost
.
2023
;
123
(
2
):
177
-
185
.
37.
Shamanaev
A
,
Ma
Y
,
Ponczek
MB
, et al
.
A model of zymogen factor XII: insights into protease activation
.
Blood Adv
.
2025
;
9
(
8
):
1940
-
1951
.
38.
Ravon
DM
,
Citarella
F
,
Lubbers
YT
,
Pascucci
B
,
Hack
CE
.
Monoclonal antibody F1 binds to the kringle domain of factor XII and induces enhanced susceptibility for cleavage by kallikrein
.
Blood
.
1995
;
86
(
11
):
4134
-
4143
.
39.
Shamanaev
A
,
Litvak
M
,
Cheng
Q
, et al
.
A site on factor XII required for productive interactions with polyphosphate
.
J Thromb Haemost
.
2023
;
21
(
6
):
1567
-
1579
.
40.
Frunt
R
,
El Otmani
H
,
Smits
S
,
Clark
CC
,
Maas
C
.
Factor XII contact activation can be prevented by targeting 2 unique patches in its epidermal growth factor-like 1 domain with a nanobody
.
J Thromb Haemost
.
2024
;
22
(
9
):
2562
-
2575
.
41.
Matafonov
A
,
Leung
PY
,
Gailani
AE
, et al
.
Factor XII inhibition reduces thrombus formation in a primate thrombosis model
.
Blood
.
2014
;
123
(
11
):
1739
-
1746
.
42.
Citarella
F
,
Ravon
DM
,
Pascucci
B
,
Felici
A
,
Fantoni
A
,
Hack
CE
.
Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces
.
Eur J Biochem
.
1996
;
238
(
1
):
240
-
249
.
43.
McMullen
BA
,
Fujikawa
K
.
Amino acid sequence of the heavy chain of human alpha-factor XIIa (activated Hageman factor)
.
J Biol Chem
.
1985
;
260
(
9
):
5328
-
5341
.
44.
Pixley
RA
,
Stumpo
LG
,
Birkmeyer
K
,
Silver
L
,
Colman
RW
.
A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation
.
J Biol Chem
.
1987
;
262
(
21
):
10140
-
10145
.
45.
Citarella
F
,
te Velthuis
H
,
Helmer-Citterich
M
,
Hack
CE
.
Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII--an immunochemical and homology modeling approach
.
Thromb Haemost
.
2000
;
84
(
6
):
1057
-
1065
.
46.
Ghebrehiwet
B
,
CebadaMora
C
,
Tantral
L
,
Jesty
J
,
Peerschke
EI
.
gC1qR/p33 serves as a molecular bridge between the complement and contact activation systems and is an important catalyst in inflammation
.
Adv Exp Med Biol
.
2006
;
586
:
95
-
105
.
47.
Khan
MM
,
Bradford
HN
,
Isordia-Salas
I
, et al
.
High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes
.
Arterioscler Thromb Vasc Biol
.
2006
;
26
(
10
):
2260
-
2266
.
48.
Joseph
K
,
Tholanikunnel
BG
,
Ghebrehiwet
B
,
Kaplan
AP
.
Interaction of high molecular weight kininogen binding proteins on endothelial cells
.
Thromb Haemost
.
2004
;
91
(
1
):
61
-
70
.
49.
Joseph
K
,
Ghebrehiwet
B
,
Kaplan
AP
.
Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells
.
Clin Immunol
.
1999
;
92
(
3
):
246
-
255
.
50.
Thompson
RE
,
Mandle
R
,
Kaplan
AP
.
Characterization of human high molecular weight kininogen. Procoagulant activity associated with the light chain of kinin-free high molecular weight kininogen
.
J Exp Med
.
1978
;
147
(
2
):
488
-
499
.
51.
Jiang
YP
,
Muller-Esterl
W
,
Schmaier
AH
.
Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets
.
J Biol Chem
.
1992
;
267
(
6
):
3712
-
3717
.
52.
Weisel
JW
,
Nagaswami
C
,
Woodhead
JL
,
DeLa Cadena
RA
,
Page
JD
,
Colman
RW
.
The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy
.
J Biol Chem
.
1994
;
269
(
13
):
10100
-
10106
.
53.
Colman
RW
,
Pixley
RA
,
Najamunnisa
S
, et al
.
Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor
.
J Clin Invest
.
1997
;
100
(
6
):
1481
-
1487
.
54.
Herwald
H
,
Mörgelin
M
,
Svensson
HG
,
Sjöbring
U
.
Zinc-dependent conformational changes in domain D5 of high molecular mass kininogen modulate contact activation
.
Eur J Biochem
.
2001
;
268
(
2
):
396
-
404
.
55.
DeLa Cadena
RA
,
Colman
RW
.
The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface
.
Protein Sci
.
1992
;
1
(
1
):
151
-
160
.
56.
Kunapuli
SP
,
DeLa Cadena
RA
,
Colman
RW
.
Deletion mutagenesis of high molecular weight kininogen light chain. Identification of two anionic surface binding subdomains
.
J Biol Chem
.
1993
;
268
(
4
):
2486
-
2492
.
57.
Jiang
J
,
Zhang
Y
,
Krainer
AR
,
Xu
RM
.
Crystal structure of human p32, a doughnut-shaped acidic mitochondrial matrix protein
.
Proc Natl Acad Sci U S A
.
1999
;
96
(
7
):
3572
-
3577
.
58.
Renné
T
,
Sugiyama
A
,
Gailani
D
,
Jahnen-Dechent
W
,
Walter
U
,
Müller-Esterl
W
.
Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2
.
Int Immunopharmacol
.
2002
;
2
(
13-14
):
1867
-
1873
.
59.
Tait
JF
,
Fujikawa
K
.
Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI
.
J Biol Chem
.
1987
;
262
(
24
):
11651
-
11656
.
60.
Mohammed
BM
,
Sun
MF
,
Cheng
Q
, et al
.
High molecular weight kininogen interactions with the homologs prekallikrein and factor XI: importance to surface-induced coagulation
.
J Thromb Haemost
.
2024
;
22
(
1
):
225
-
237
.
61.
Li
C
,
Barroeta
AB
,
Wong
SS
, et al
.
Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites
.
J Thromb Haemost
.
2023
;
21
(
9
):
2378
-
2389
.
62.
Bar Barroeta
A
,
Albanese
P
,
Kadavá
T
, et al
.
Thrombin activation of the factor XI dimer is a multistaged process for each subunit
.
J Thromb Haemost
.
2024
;
22
(
5
):
1336
-
1346
.
63.
Chen
ZL
,
Singh
PK
,
Horn
K
,
Strickland
S
,
Norris
EH
.
Anti-HK antibody reveals critical roles of a 20-residue HK region for Aβ-induced plasma contact system activation
.
Blood Adv
.
2022
;
6
(
10
):
3090
-
3101
.
64.
Chen
ZL
,
Singh
PK
,
Horn
K
, et al
.
Anti-HK antibody inhibits the plasma contact system by blocking prekallikrein and factor XI activation in vivo
.
Blood Adv
.
2023
;
7
(
7
):
1156
-
1167
.
65.
McMullen
BA
,
Fujikawa
K
,
Davie
EW
.
Location of the disulfide bonds in human plasma prekallikrein: the presence of four novel apple domains in the amino-terminal portion of the molecule
.
Biochemistry
.
1991
;
30
(
8
):
2050
-
2056
.
66.
Chung
DW
,
Fujikawa
K
,
McMullen
BA
,
Davie
EW
.
Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats
.
Biochemistry
.
1986
;
25
(
9
):
2410
-
2417
.
67.
Li
C
,
Voos
KM
,
Pathak
M
, et al
.
Plasma kallikrein structure reveals apple domain disc rotated conformation compared to factor XI
.
J Thromb Haemost
.
2019
;
17
(
5
):
759
-
770
.
68.
Papagrigoriou
E
,
McEwan
PA
,
Walsh
PN
,
Emsley
J
.
Crystal structure of the factor XI zymogen reveals a pathway for transactivation
.
Nat Struct Mol Biol
.
2006
;
13
(
6
):
557
-
558
.
69.
Bar Barroeta
A
,
van Galen
J
,
Stroo
I
,
Marquart
JA
,
Meijer
AB
,
Meijers
JCM
.
Hydrogen-deuterium exchange mass spectrometry highlights conformational changes induced by factor XI activation and binding of factor IX to factor XIa
.
J Thromb Haemost
.
2019
;
17
(
12
):
2047
-
2055
.
70.
Kearney
KJ
,
Butler
J
,
Posada
OM
, et al
.
Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI
.
Proc Natl Acad Sci U S A
.
2021
;
118
(
3
):
e2014810118
.
71.
Visser
M
,
van Oerle
R
,
Ten Cate
H
, et al
.
Plasma kallikrein contributes to coagulation in the absence of factor XI by activating factor IX
.
Arterioscler Thromb Vasc Biol
.
2020
;
40
(
1
):
103
-
111
.
72.
Osterud
B
,
Laake
K
,
Prydz
H
.
The activation of human factor IX
.
Thromb Diath Haemorrh
.
1975
;
33
(
3
):
553
-
563
.
73.
Noubouossie
DF
,
Henderson
MW
,
Mooberry
M
, et al
.
Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways
.
Blood
.
2020
;
135
(
10
):
755
-
765
.
74.
Moellmer
SA
,
Puy
C
,
McCarty
OJT
.
Biology of factor XI
.
Blood
.
2024
;
143
(
15
):
1445
-
1454
.
75.
Emsley
J
,
McEwan
PA
,
Gailani
D
.
Structure and function of factor XI
.
Blood
.
2010
;
115
(
13
):
2569
-
2577
.
76.
Baglia
FA
,
Walsh
PN
.
A binding site for thrombin in the apple 1 domain of factor XI
.
J Biol Chem
.
1996
;
271
(
7
):
3652
-
3658
.
77.
Baglia
FA
,
Jameson
BA
,
Walsh
PN
.
Identification and characterization of a binding site for factor XIIa in the Apple 4 domain of coagulation factor XI
.
J Biol Chem
.
1993
;
268
(
6
):
3838
-
3844
.
78.
Shearin
S
,
Venkateswarlu
D
.
Structural insights into the activation of blood coagulation factor XI zymogen by thrombin: a computational molecular dynamics study
.
Biophys Chem
.
2022
;
281
:
106737
.
79.
Geng
Y
,
Verhamme
IM
,
Smith
SB
, et al
.
The dimeric structure of factor XI and zymogen activation
.
Blood
.
2013
;
121
(
19
):
3962
-
3969
.
80.
Ivanov
I
,
Matafonov
A
,
Sun
MF
, et al
.
Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation
.
Blood
.
2017
;
129
(
11
):
1527
-
1537
.
81.
Ivanov
I
,
Verhamme
IM
,
Sun
MF
, et al
.
Protease activity in single-chain prekallikrein
.
Blood
.
2020
;
135
(
8
):
558
-
567
.
82.
Wang
Y
,
Ivanov
I
,
Smith
SA
,
Gailani
D
,
Morrissey
JH
.
Polyphosphate, Zn2+ and high molecular weight kininogen modulate individual reactions of the contact pathway of blood clotting
.
J Thromb Haemost
.
2019
;
17
(
12
):
2131
-
2140
.
83.
Naudin
C
,
Burillo
E
,
Blankenberg
S
,
Butler
L
,
Renné
T
.
Factor XII contact activation
.
Semin Thromb Hemost
.
2017
;
43
(
8
):
814
-
826
.
84.
Oschatz
C
,
Maas
C
,
Lecher
B
, et al
.
Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo
.
Immunity
.
2011
;
34
(
2
):
258
-
268
.
85.
Müller
F
,
Mutch
NJ
,
Schenk
WA
, et al
.
Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo
.
Cell
.
2009
;
139
(
6
):
1143
-
1156
.
86.
Smith
SB
,
Verhamme
IM
,
Sun
MF
,
Bock
PE
,
Gailani
D
.
Characterization of novel forms of coagulation factor XIa: independence of factor XIa subunits in factor IX activation
.
J Biol Chem
.
2008
;
283
(
11
):
6696
-
6705
.
87.
Gailani
D
,
Geng
Y
,
Verhamme
I
, et al
.
The mechanism underlying activation of factor IX by factor XIa
.
Thromb Res
.
2014
;
133 suppl 1
(
0 1
):
S48
-
S51
.
You do not currently have access to this content.
Sign in via your Institution